Joint Formulary & PAD

Cabergoline - Parkinson's disease (neuroprotective therapy)

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Non Formulary
Formulations :
  • Tablets
Associated Icons :
NFD1
SPC
Restrictions / Comments :

Documentation

PAD Profile

ChemicalSubstance :
Cabergoline
Indication :
Parkinson's disease (neuroprotective therapy)
Group Name :
Keywords :
dopamine agonists, non-ergot-derived dopamine receptor agonists, Parkinsons disease, PD
Brand Names Include :
Cabaser, Dostinex
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
1

Other Indications

Below are listed other indications that Cabergoline is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Parkinson's disease (neuroprotective therapy).

Committee Recommendations (1)

Dopamine agonists are not recommended as a neuroprotective therapy except in the context of a clinical trial